MARGENZA 25 mg/mL
margetuximab-cmkb · INJECTION, SOLUTION, CONCENTRATE · TerSera Therapeutics LLC
MARGENZA is a injection, solution, concentrate containing margetuximab-cmkb at 25 mg/mL, taken intravenous. Manufactured by TerSera Therapeutics LLC.
Key Facts
- Brand Name
- MARGENZA
- Generic Name
- margetuximab-cmkb
- NDC Code (Product)
70720-022- Manufacturer
- TerSera Therapeutics LLC
- Strength
- 25 mg/mL
- Dosage Form
- INJECTION, SOLUTION, CONCENTRATE
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761150
- Drug Class
- HER2/neu Receptor Antagonist [EPC]
- Marketing Start
- 01/15/2021
Recall History
No Recall HistoryFrequently Asked Questions
What is MARGENZA used for?
MARGENZA contains margetuximab-cmkb. It is a injection, solution, concentrate taken intravenous. Consult your doctor for specific uses.
Is MARGENZA a controlled substance?
MARGENZA is not classified as a controlled substance by the DEA.
What is the generic name for MARGENZA?
The generic name for MARGENZA is margetuximab-cmkb. There are no other listed brand versions of margetuximab-cmkb.
What is the NDC code for MARGENZA 25 mg/mL?
The NDC (National Drug Code) for MARGENZA 25 mg/mL is 70720-022, listed by TerSera Therapeutics LLC.
Product NDC
70720-022
Other MARGENZA Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)